KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Equity Income (2021 - 2025)

Vir Biotechnology's Equity Income history spans 5 years, with the latest figure at -$2.6 million for Q4 2025.

  • For Q4 2025, Equity Income fell 124.74% year-over-year to -$2.6 million; the TTM value through Dec 2025 reached $1.7 million, up 131.44%, while the annual FY2025 figure was $1.7 million, 131.44% up from the prior year.
  • Equity Income for Q4 2025 was -$2.6 million at Vir Biotechnology, down from $1.3 million in the prior quarter.
  • Across five years, Equity Income topped out at $164.1 million in Q3 2021 and bottomed at -$95.0 million in Q1 2022.
  • The 5-year median for Equity Income is -$2.6 million (2023), against an average of $70611.1.
  • The largest YoY upside for Equity Income was 208.47% in 2025 against a maximum downside of 916.91% in 2025.
  • A 5-year view of Equity Income shows it stood at -$26.0 million in 2021, then soared by 134.27% to $8.9 million in 2022, then crashed by 111.21% to -$1.0 million in 2023, then decreased by 14.4% to -$1.1 million in 2024, then crashed by 124.74% to -$2.6 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Equity Income are -$2.6 million (Q4 2025), $1.3 million (Q3 2025), and -$3.4 million (Q2 2025).